目的 探討燈盞細(xì)辛注射液聯(lián)合依達(dá)拉奉注射液治療高血壓腦出血的臨床療效。方法 選取上海市靜安區(qū)閘北中心醫(yī)院在2023年4月—2024年3月收治的100例高血壓腦出血患者，按隨機(jī)數(shù)字表法分為對照組和治療組，每組50例。對照組靜脈滴注依達(dá)拉奉注射液，2次/d，3支/次，加入適量生理鹽水在30 min內(nèi)滴完。治療組在對照組基礎(chǔ)上靜脈滴注燈盞細(xì)辛注射液，1次/d，40 mL/次，加入250 mL生理鹽水充分稀釋后滴注。兩組持續(xù)治療14 d。比較兩組的臨床療效、神經(jīng)功能、顱內(nèi)血管狀態(tài)、腦血管功能和血清指標(biāo)。結(jié)果 治療組的總有效率較對照組更高，差異有統(tǒng)計(jì)學(xué)意義（96.00% vs 84.00%，P＜0.05）。治療后，兩組的國家衛(wèi)生研究院卒中評分量表（NIHSS）評分均降低（P＜0.05），治療組的NIHSS評分較對照組更低（P＜0.05）。治療后，兩組的腦血腫量、水腫量、半暗帶面積較治療前降低（P＜0.05），治療組的腦血腫量、水腫量、半暗帶面積與對照組比較更低（P＜0.05）。治療后，兩組的動態(tài)阻力、周圍阻力均降低，平均流速升高（P＜0.05）；治療組的動態(tài)阻力、周圍阻力低于對照組，平均流速高于對照組（P＜0.05）。治療后兩組的血清白細(xì)胞介素-18（IL-18）、熱休克蛋白47（HSP47）、CD163、中樞神經(jīng)特異性蛋白S100β（S100β）水平均降低（P＜0.05）；治療組的血清IL-18、HSP47、CD163、S100β水平低于對照組（P＜0.05）。結(jié)論 燈盞細(xì)辛注射液聯(lián)合依達(dá)拉奉注射液可提高高血壓腦出血的治療效果，改善神經(jīng)功能，降低腦血腫癥狀，改善腦血管功能，降低神經(jīng)炎性損傷。

Objective To investigate the clinical efficacy of Dengzhan Xixin Injection combined with Edaravone Injection in treatment of hypertensive intracerebral hemorrhage. Methods 100 Patients with hypertensive intracerebral hemorrhage were divided into two groups, with 50 cases every group. The control group patients were treated with intravenous infusion of Edaravone Injection, twice daily, 15 mL each time. On the basis of the control group, patients in the treatment group received intravenous drip of Dengzhan Xixin Injection, once daily, 40 mL/time. Two groups were treated for 14 d. The clinical efficacy, neurological function, intracranial vascular status, cerebrovascular function, and serum indicators between two groups were compared. Results The total effective rate of the treatment group was higher than that of the control group (96.00% vs 84.00%, P < 0.05). NIHSS scores of both groups were decreased (P < 0.05), and NIHSS scores in the treatment group was lower than those of the control group (P < 0.05). After treatment, the amount of cerebral hematoma, edema, and penumbra area in both groups were decreased (P < 0.05). Compared with the control group, the treatment group had lower amounts of cerebral hematoma, edema, and penumbra area (P < 0.05). The dynamic resistance and peripheral resistance of both groups were decreased, but the average flow velocity was increased (P < 0.05). The dynamic resistance and peripheral resistance of the treatment group were lower than those of the control group, but the average flow velocity was higher than that of the control group after treatment (P < 0.05). After treatment, the levels of IL-18, HSP47, CD163, and S100β in both groups were decreased (P < 0.05), and these factors in the treatment group were lower than those in the control group (P < 0.05).Conclusion The combination of Dengzhan Xixin Injection and Edaravone Injection can improve the therapeutic effect of hypertensive intracerebral hemorrhage, improve neurological function, reduce symptoms of cerebral hematoma, improve cerebrovascular function, and reduce neuroinflammatory injury.

R971

上海市“十四五”中醫(yī)特色專科和中醫(yī)急診能力提升（第一批）項(xiàng)目（ZYTSZK2-6）